Differential Associations Between Specific Depressive Symptoms and Cardiovascular Prognosis in Patients With Stable Coronary Heart Disease  by Hoen, Petra W. et al.
B
l
a
i
p
F
t
G
s
C
a
M
R
L
Journal of the American College of Cardiology Vol. 56, No. 11, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
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Differential Associations
Between Specific Depressive Symptoms
and Cardiovascular Prognosis in
Patients With Stable Coronary Heart Disease
Petra W. Hoen, BSC,* Mary A. Whooley, MD,§ Elisabeth J. Martens, PHD,‡ Beeya Na, MPH,§
Joost P. van Melle, MD,† Peter de Jonge, PHD*‡
Groningen and Tilburg, the Netherlands; and San Francisco, California
Objectives The purpose of this research was to evaluate the relationship between cognitive and somatic depressive symp-
toms and cardiovascular prognosis.
Background Depression in patients with stable coronary heart disease (CHD) is associated with poor cardiac prognosis.
Whether certain depressive symptoms are more cardiotoxic than others is unknown.
Methods In the Heart and Soul Study, 1,019 patients with stable CHD were assessed using the Patient Health Question-
naire to determine the presence of the 9 depressive symptoms included in the Diagnostic and Statistical Manual
of Mental Disorders–Fourth Edition. The mean age of the patients was 67 years, and 82% were men. A compari-
son was made on a new cardiovascular event (myocardial infarction, stroke, transient ischemic attack, or con-
gestive heart failure) or death (mean follow-up duration 6.1  2.0 years) on the basis of cognitive and somatic
sum scores and for patients with or without each of those specific depressive symptoms. Demographic charac-
teristics, cardiac risk factors, and cardiac medications were controlled for.
Results After adjustment for demographic data and cardiac risk factors, each somatic symptom was associated with
14% greater risk for events (hazard ratio [HR]: 1.14; 95% confidence interval [CI]: 1.05 to 1.24; p  0.002).
Fatigue (HR: 1.34; 95% CI: 1.07 to 1.67; p  0.01), appetite problems (HR: 1.46; 95% CI: 1.12 to 1.91; p 
0.005), and sleeping difficulties (HR: 1.26; 95% CI: 1.00 to 1.58; p  0.05) were most strongly predictive of car-
diovascular events. In contrast, cognitive symptoms (HR: 1.08; 95% CI: 0.99 to 1.17; p  0.09) were not signifi-
cantly associated with cardiovascular events.
Conclusions In patients with stable CHD, somatic symptoms of depression were more strongly predictive of cardiovascular
events than cognitive symptoms, although the CIs surrounding these estimates had substantial overlap. These
findings are highly consistent with those of previous studies. Further research is needed to understand the
pathophysiological processes by which somatic depressive symptoms contribute to prognosis in patients with
CHD. (J Am Coll Cardiol 2010;56:838–44) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.080c
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Ay 2020, the most important causes of disability-adjusted
ife-years are predicted to be coronary heart disease (CHD)
nd major depression (1). Patients with CHD are at
ncreased risk for developing depression (2). Likewise,
atients with depression are at increased risk for developing
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September 7, 2010:838–44 Depressive Symptoms, Stable CHD, and Prognosisate the efficacy of antidepressant therapy in patients with
HD. However, in most of these studies, treatment had
nly minor effects on reducing depressive symptoms (8).
A reason for these findings may be the heterogeneity of
epression as a syndrome (9). Depression is a syndrome
onsisting of 9 depressive symptoms, according to the
riteria of the Diagnostic and Statistical Manual of Mental
isorders-Fourth Edition (10). Several researchers over
ime have distinguished somatic symptoms from cognitive
ymptoms of depression (11–13). In recent years, this
istinction has been applied to patients with CHD (14). It
as been found that somatic symptoms of depression had a
elatively high prevalence (15) and were more strongly
ssociated with CV prognosis (14,16–18), medical comor-
idity (13), and heart rate variability (19). At this time, it
emains to be determined which of these symptoms has the
ost cardiotoxic contribution in terms of CV prognosis in
atients with stable CHD.
We hypothesized the existence of differential associations
f specific depressive symptoms with CV prognosis. We
hose to investigate this research question in a population
ith stable CHD because in this sample, depressive symp-
oms may be less confounded by symptoms that are fre-
uently expressed in the direct aftermath of an acute
oronary event, such as fatigue. The identification of certain
ardiotoxic symptoms within the diagnosis of depression
ould be an important step in the development of antide-
ressive interventions that aim to alleviate the depression-
ssociated risk of CV events.
ethods
esign and patients. This study was based on data from
he Heart and Soul Study, a prospective cohort study
ocused on psychosocial factors and health outcomes in
atients with stable CHD. Details regarding the methods of
he Heart and Soul Study have been described previously
20). Patients had to meet the following inclusion criteria:
) history of MI or coronary revascularization; 2) angio-
raphic evidence of at least 50% stenosis in at least 1
oronary vessel; and 3) a diagnosis of CHD by an internist
r cardiologist. Exclusion criteria were 1) a history of MI in
he past 6 months; 2) poor exercise tolerance (inability to
alk 1 block); and 3) planning to move from the local area
ithin 3 years.
We initially mailed letters to 15,438 patients who had
nternational Classification of Diseases-9th Revision codes for
HD based on administrative databases at 2 U.S. Department
f Veterans Affairs medical centers, 1 university medical center,
nd 9 public health clinics in northern California. Because
dministrative data are not necessarily correct or current, many
f these letters were mailed to bad addresses or to persons who
id not meet eligibility criteria. Of the 2,495 patients who
eturned the form indicating that they would be interested in
articipating, 370 were excluded on the basis of the pre-
efined exclusion criteria, and 505 could not be reached by 9elephone. Of the 1,620 patients
ho were confirmed to meet the
ligibility criteria, 596 declined to
articipate, and 1,024 (63%) en-
olled. Between September 2000
nd December 2002, all partici-
ants completed a baseline assess-
ent, including a medical history
nterview, a fasting blood draw, a
hysical examination, an exercise
readmill test with stress echocar-
iography, a comprehensive health
tatus questionnaire, and 24-h urine collection. All participat-
ng patients signed informed consent forms. The study proto-
ol was approved by the institutional review boards of the
articipating hospitals.
aseline characteristics. Baseline characteristics of the
tudy sample included sociodemographic data, history of
V disease, and cardiac disease severity. The sociodemo-
raphic characteristics were age, sex, and marital status and
ere determined by questionnaire. History of CV disease
as determined by self-report and included MI, congestive
eart failure, and stroke. All participants underwent resting
chocardiography using an Acuson Sequoia ultrasound sys-
em (Siemens Medical Solutions USA, Inc., Mountain
iew, California) with a 3.5-MHz transducer. Standard
-dimensional views and performed planimetry with a
omputerized digitization system were obtained to deter-
ine left ventricular ejection fraction. Smoking was deter-
ined by self-report, and body mass index was assessed.
articipants were instructed to bring their medication bot-
les to their appointments, and study personnel recorded all
urrent medications, including dose and frequency use.
ssessment of depressive symptoms. The 9-item Patient
ealth Questionnaire (PHQ) (10) was used to determine the
resence and severity of the 9 depressive symptoms listed in the
iagnostic and Statistical Manual of Mental Disorders-Fourth
dition. The PHQ is a self-report checklist derived from the
nterview used in the Primary Care Evaluation of Mental
isorders (21). This instrument measures the presence of
epressive symptoms during the previous 2 weeks, each scored
s follows: 0  not at all, 1  several days, 2  more than
ne-half of the days, or 3  nearly every day.
This study evaluated the effect of each depressive symp-
om both as a dichotomous variable using the standard cut
oint of 2 for the presence of the first 8 depressive
ymptoms and 1 for the presence of the symptom suicidal
deation (in concordance with the manual) (10) and as
log-transformed continuous variable. The 9 symptoms
f depression in the PHQ, based on the classification of
epression in the Diagnostic and Statistical Manual of
ental Disorders-Fourth Edition, are: 1) depressed mood;
) loss of interest; 3) appetite problems; 4) sleeping diffi-
ulties; 5) psychomotor agitation or retardation; 6) fatigue;
) feelings of worthlessness; 8) concentration problems; and
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
CV  cardiovascular
HR  hazard ratio
MI  myocardial infarction
PHQ  Patient Health
Questionnaire) suicidal ideation.
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Depressive Symptoms, Stable CHD, and Prognosis September 7, 2010:838–44omatic and cognitive depressive symptoms. Following
arlier work, depressive symptoms were categorized as follows:
epressed mood, lack of interest, worthlessness, concentration
roblems, and suicidal ideation were considered to be cognitive
ymptoms, and appetite problems, sleeping difficulties, psy-
homotor agitation or retardation, and fatigue were considered
o be somatic symptoms (18,19).
nd points and follow-up. After the baseline examination,
e conducted annual telephone follow-up interviews with
articipants (or their proxies), asking specifically about hospi-
alization for “heart trouble.” For any reported event, medical
ecords, electrocardiograms, death certificates, and coroners’
eports were retrieved and reviewed by 2 independent blinded
djudicators. In the event of disagreement, the adjudicators
onferred, reconsidered their classification, and requested con-
ultation from a third blinded adjudicator as necessary. The
rimary study end points were CV events, including heart
ailure, MI, stroke, transient ischemic attack, or death.
For patients to be diagnosed with heart failure, they had
o be hospitalized for a clinical syndrome meeting at least 2
f the following criteria: paroxysmal nocturnal dyspnea,
rthopnea, elevated jugular venous pressure, pulmonary
ales, third heart sound, and cardiomegaly or pulmonary
dema on chest radiography. A clear change in these
ymptoms from the patients’ usual clinical status and either
eripheral hypoperfusion (in the absence of other causes) or
eripheral or pulmonary edema requiring intravenous di-
retic, inotropic, or vasodilator therapy was a necessary
ondition (22). Standard criteria were used for defining
onfatal MI (23). Stroke was defined as new neurological
eficit, which must not have been the result of brain trauma,
umor, infection, or other cause. Transient ischemic attack
as defined as a focal neurological deficit (in the absence of
ead trauma) lasting between 30 s and 24 h, with rapid
volution of the symptoms to the maximal level of deficit in
5 min and with subsequent complete resolution. Death
as determined by death certificates and coroners’ reports.
tatistical analysis. We used Cox proportional hazards
egression (i.e., survival analysis) to estimate the differential
ffects of the 9 depressive symptoms on cardiac events.
azard ratios (HRs) with 95% confidence intervals (CIs)
re reported. The Cox regression procedure is a method of
stimating time-to-event models in the presence of cen-
ored cases. Cases are censored either at the occurrence of
he first CV event or at the end of follow-up, whichever
omes first. Cox regression analyses were conducted for
valuating the effects of each specific depressive symptom,
ontrolling for age and sex. Second, multivariate effects were
valuated after controlling for variables previously found to
redict CV events in this cohort (age, sex, diabetes mellitus,
istory of MI, history of stroke, history of heart failure, left
entricular ejection fraction, body mass index, and smoking)
22) and for use of cardioprotective medications (aspirin,
eta-blockers, statins, and renin-angiotensin system inhib-
tors). Each depressive symptom was entered both as a
og-transformed continuous variable and as a dichotomous
Dariable. Interactions were checked between the specific
epressive symptoms and sex and age. All statistical analyses
ere performed using SPSS version 14.0 (SPSS, Inc.,
hicago, Illinois).
esults
f the 1,024 enrolled patients with CHD, 1,019 (99%)
ere available for follow-up. Patient characteristics are
resented in Table 1. The prevalence of each specific
epressive symptom is presented in Table 2. A total of 399
vents occurred (MI, heart failure, stroke, transient ischemic
ttack, or death) during an average of 6.1  2.0 years of
ollow-up.
In age-adjusted analyses, both somatic and cognitive
ymptoms were associated with an increased risk for CV
vents. The annual rate of events ranged from 5.9% among
hose with no somatic symptoms to 12.6% among those
ith 4 somatic symptoms and from 6.4% among those with
o cognitive symptoms to 11.4% among those with 5
ognitive symptoms (Fig. 1). Each somatic symptom was
ssociated with a 21% increased rate of CV events (HR:
.21; 95% CI: 1.11 to 1.31; p  0.0001), and this associa-
ion remained strong after adjustment for potential con-
ounding variables (HR: 1.14; 95% CI: 1.05 to 1.24)
Table 2). Each cognitive symptom was associated with a
2% increased rate of CV events in age-adjusted analyses
HR: 1.12; 95% CI: 1.03 to 1.21; p  0.006). After further
djustment for potential confounding variables, the cogni-
ive sum score did not significantly predict CV events (HR:
.08; 95% CI: 0.99 to 1.17; p  0.09).
When entered as dichotomous variables, several symp-
oms were associated with CV events in age-adjusted
odels. After further adjustment for age, sex, diabetes
ellitus, history of MI, history of stroke, history of heart
ailure, left ventricular ejection fraction, body mass index,
moking, and use of cardioprotective medications, 3 of the
aseline Characteristics ofhe Study S mple (n  1,019)Table 1 B s line Characteristics ofthe Study Sample (n  1,019)
Age (yrs) 67 11
Men 836 (82%)
Married 436 (43%)
History of MI 545 (54%)
History of CHF 179 (18%)
History of stroke 148 (15%)
Diabetes mellitus 265 (26%)
Left ventricular ejection fraction 0.62 0.10
Current smoking 199 (20%)
Body mass index (kg/m2) 28 5
Aspirin 790 (78%)
Beta-blockers 591 (58%)
Statins 655 (64%)
Renin-angiotensin system inhibitors 524 (51%)
Antidepressant agents 187 (18%)ata are expressed as mean  SD or as n (%).
CHF  congestive heart failure; MI  myocardial infarction.
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September 7, 2010:838–44 Depressive Symptoms, Stable CHD, and Prognosisomatic symptoms (fatigue, appetite problems, and sleeping
ifficulties) were independently predictive of CV events
Table 2). These were also the 3 most common symptoms.
one of the cognitive symptoms were independently pre-
ictive of CV events. We observed no evidence for an
nteraction of specific depressive symptoms with age or sex
n predicting CV events (all p values for interaction  NS).
n Figure 2, the HRs and 95% CIs of specific depressive
ymptoms with CV events are visualized in a forest plot.
When each depressive symptom was entered as a log-
ransformed continuous variable, the following symptoms were
ssociated with poor cardiac prognosis: fatigue (p  0.0001),
ppetite problems (p  0.0001), sleeping difficulties (p 
ge-Adjusted Annual Rate of CV Events (MI, CHF, Stroke, TIA, or Dmong Participa ts With and Without Specific Depressive SymptomTable 2 Age-Adjusted Annual Rate of CV Events (MI, CHF, S roAmong Participants With and Without Specific Depres
Symptom
With Symptoms Without S
n
Age-Adjusted
Event Rate n
Ag
E
Somatic symptoms
Fatigue 267 9.1% 746
Appetite problems 160 11.1% 858
Psychomotor agitation/retardation 85 9.3% 934
Sleeping difficulties 249 8.7% 766
Somatic sum score†
Cognitive symptoms
Depressed mood 114 9.7% 900
Lack of interest 129 9.8% 889
Worthlessness 114 9.1% 904
Concentration problems 129 8.2% 890
Suicidal ideation 111 8.4% 908
Cognitive sum score†
Adjusted for age, sex, diabetes mellitus, history of MI, history of stroke, history of heart failure
enin-angiotensin system inhibitor use. †Entered as a continuous variable.
CI  confidence interval; CV  cardiovascular; HR  hazard ratio; TIA  transient ischemic atta
Figure 1 Age-Adjusted Annual Rate of CV Events (MI, Heart Fa
During an Average of 6.1 Years of Follow-Up by Numb
The somatic sum score is the number of somatic symptoms with scores 2; the c
number of cognitive symptoms with scores 2 (or 1 for suicidal ideation). CV .03), depressed mood (p 0.005), and suicidal ideation (p
.02) (Table 3). After multivariate adjustment, only fatigue and
ppetite problems remained significantly associated with CV
vents. Thus, when entered as continuous variables, 2 of 4
omatic symptoms and none of the cognitive symptoms were
ndependently predictive of CV events (Table 3).
iscussion
n a sample of 1,019 patients with stable CHD, we
valuated the association between specific symptoms of
epression and CV events. Both somatic and cognitive
ymptoms were associated with an increased risk for CV
)IA, or Death)
ymptoms
ms
Age-Adjusted HR
(95% CI) p Value
Fully Adjusted HR
(95% CI)* p Value
sted
ate
1.49 (1.20–1.84) 0.0003 1.34 (1.07–1.67) 0.01
1.76 (1.37–2.28) 0.0001 1.46 (1.12–1.91) 0.005
1.39 (0.99–1.95) 0.06 1.31 (0.93–1.85) 0.13
1.38 (1.11–1.72) 0.004 1.26 (1.00–1.58) 0.05
1.21 (1.11–1.31) 0.0001 1.14 (1.05–1.24) 0.002
1.48 (1.10–1.99) 0.01 1.32 (0.97–1.80) 0.08
1.50 (1.14–1.97) 0.004 1.21 (0.91–1.61) 0.19
1.36 (0.99–1.86) 0.06 1.22 (0.88–1.69) 0.23
1.22 (0.90–1.64) 0.19 1.10 (0.81–1.49) 0.55
1.26 (0.92–1.71) 0.15 1.25 (0.91–1.72) 0.18
1.12 (1.03–1.21) 0.006 1.08 (0.99–1.17) 0.09
ntricular ejection fraction, body mass index, smoking aspirin, beta-blocker use, statin use, and
er abbreviations as in Table 1.
Stroke, Transient Ischemic Attack, or Death)
Somatic or Cognitive Depressive Symptoms
ve sum score is the
vascular; MI  myocardial infarction.eathske, T
sive S
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e-Adju
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6.1%
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6.7%
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Depressive Symptoms, Stable CHD, and Prognosis September 7, 2010:838–44vents. However, after adjustment for CV risk factors and
isease severity, somatic symptoms appeared to be more
trongly predictive of CV events than cognitive symptoms
f depression. Fatigue, appetite problems, and sleeping
ifficulties were the symptoms most strongly predictive of
V events. These results may be of importance for identi-
ying depressed patients who are at highest risk for devel-
ping CV events and for identifying potential therapies to
mprove CV outcomes in patients with CHD.
Earlier studies have found that somatic symptoms of
epression are more strongly predictive of CV events than
ognitive symptoms of depression (14,16–18). However,
iven the high prevalence of somatic symptoms such as
atigue, loss of appetite, and sleeping difficulties in patients
fter MI, it was unclear whether these findings were
estricted to this patient population. Our study extends
hese findings to outpatients with stable CHD by demon-
trating that somatic symptoms are more strongly predictive
f CV events in this patient population.
Figure 2 Association Between Specific Depressive Symptoms (
Hazard ratios (HRs) with 95% confidence intervals, adjusted for age, sex, diabetes
ventricular ejection fraction, body mass index, smoking, aspirin, beta-blocker use,
Bivariate and Multivariate Associations of Spec(Entered s Continuous Variables) With CV EvenTable 3 Bivariate and Multivariate Associat(Entered as Continuous Variables) W
Symptom HR* (95% C
Somatic symptoms
Fatigue 1.21 (1.10–1.
Appetite problems 1.27 (1.15–1.
Psychomotor agitation/retardation 1.14 (1.00–1.
Sleeping difficulties 1.11 (1.01–1.
Cognitive symptoms
Lack of interest 1.11 (0.99–1.
Depressed mood 1.19 (1.05–1.
Worthlessness 1.11 (0.98–1.
Concentration problems 1.02 (0.90–1.
Suicidal ideation 1.25 (1.03–1.
*Adjusted for age and sex. †Adjusted for age, sex, diabetes mellitus, h
fraction, body mass index, smoking aspirin, beta-blocker use, statin use, and
Abbreviations as in Tables 1 and 2.It is difficult to ascertain whether somatic depressive
ymptoms are due to depression or to worse underlying
eart disease. Indeed, on the basis of our findings, one
ight conclude that general somatic malaise or fatigue (not
epression) is the predictor of poor outcomes. However, we
ried to overcome this difficulty by carefully measuring and
djusting for history of MI, diabetes, left ventricular ejection
raction, smoking, body mass index, and use of cardiopro-
ective medications. The extent to which differences in these
ariables explained the effect of somatic symptoms on CV
vents appeared to be limited, as bivariate and adjusted
ffects on CV prognosis were highly comparable. In addi-
ion, we purposefully enrolled a uniform sample of patients
ith stable CHD so that the association between depressive
ymptoms and cardiac prognosis would not be confounded
y the severity of a recent acute coronary event. Finally,
lthough fatigue, appetite problems, and sleeping difficulties
ere the strongest predictors of CV events, these were also
he most common depressive symptoms in this population.
red as Dichotomous Variables) and CV Events
us, history of MI, history of stroke, history of heart failure, left
use, and renin-angiotensin system inhibitor use. Abbreviations as in Figure 1.
epressive Symptomsof Specific Depressive Symptoms
CV Events
p Value* HR† (95% CI) p Value†
0.0001 1.15 (1.04–1.27) 0.007
0.0001 1.17 (1.06–1.30) 0.003
0.05 1.12 (0.98–1.28) 0.10
0.03 1.07 (0.98–1.18) 0.14
0.07 1.04 (0.93–1.17) 0.48
0.005 1.13 (1.00–1.28) 0.05
0.09 1.10 (0.97–1.25) 0.15
0.75 1.00 (0.88–1.13) 0.94
0.02 1.14 (0.94–1.39) 0.19
f MI, history of stroke, history of heart failure, left ventricular ejectionEnte
mellit
statinific Dtsons
ith
I)
33)
41)
29)
21)
25)
33)
26)
15)
53)
istory o
renin-angiotensin system inhibitor use.
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September 7, 2010:838–44 Depressive Symptoms, Stable CHD, and Prognosisor example, depressed mood was associated with a 32%
ncreased rate of CV events (HR: 1.32; 95% CI: 0.97 to
.80; p  0.08), but only 114 participants had depressed
ood. In contrast, fatigue was associated with a 34%
ncreased rate of CV events, but the 267 participants with
atigue yielded a tighter CI (HR: 1.34; 95% CI: 1.07 to
.67; p  0.01). Thus, the lack of an association between
ognitive symptoms and CV events may be due in part to
maller number of patients with cognitive symptoms.
In this study, specific depressive symptoms on the basis of
he PHQ were used. Major depressive disorder as measured
y the computerized Diagnostic Interview Schedule did not
redict CV events in the Heart and Soul Study (22),
hereas self-reported depressive symptoms as measured by
he PHQ strongly predicted CV events. It is unclear why
his discrepancy occurred. It is possible that participants felt
ore comfortable reporting depressive symptoms on an
nonymous questionnaire than in a face-to-face interview,
aking the interview a less accurate measure of depression.
Only 1 randomized trial has been adequately powered to
valuate the effect of depression treatment on CV prognosis
n CAD patients. The Enhancing Recovery in Coronary
eart Disease Patients trial showed that cognitive behav-
oral therapy decreased depression and improved social
upport but did not affect CV prognosis. One possible
xplanation for the lack of benefit is that patients with
HD may have depressive symptoms below the threshold
evels required for antidepressant treatment to be of benefit.
wo recent studies (24,25) have suggested that patients with
ower grade depression may not benefit from antidepressant
reatment as much as those with more severe symptoms. If
ost patients with CHD have low levels of depressive symp-
oms, then antidepressant treatment might not be effective.
lthough some nonrandomized studies of post-MI patients
ave shown that use of antidepressants or a reduction in
epressive symptoms was associated with a decreased risk for
V events (26–28), the observational design of these studies
revents a firm conclusion regarding causality.
Our present findings provide further support for the
onceptualization of depression as a heterogeneous syn-
rome in which some aspects may be more strongly related
o CV prognosis than others. This raises the possibility that
o improve CV outcomes, interventions for depression
hould be specifically directed at somatic symptoms. Cog-
itive depressive symptoms, such as feelings of worthless-
ess and suicidal ideation, have been specific targets for
ntervention in psychotherapy (29), while exercise interven-
ions, for example, may specifically improve somatic symp-
oms, perhaps even irrespective of depression (22,30). How-
ver, interventions for depression such as cognitive
ehavioral therapy or antidepressant medication therapy
robably affect both cognitive and somatic symptoms, so the
pecificity with which somatic symptoms can be targeted
ith standard interventions for depression is unclear. Per-
aps efforts should be made to improve rates of exercise uptaken patients with CHD, regardless of depression status, partic- Clarly given the known CHD benefits of exercise and the very
ow rate of adherence to this basic recommendation in both
epressed and nondepressed patients.
To achieve a better understanding of the syndrome of
epression and to develop effective treatments, it is impor-
ant to identify potential mechanisms that may underlie the
ssociation between depression and coronary disease (31).
arlier studies examined how depression may lead to
dverse clinical outcomes (32–35). In a previous report from
he Heart and Soul Study, it was concluded that somatic
epressive symptoms were associated with lower heart rate
ariability, whereas cognitive depressive symptoms were not
19). There are also studies that point to inflammation as an
mportant mechanism underlying the relation between de-
ression and CV prognosis (36). Inflammation also may be
ore strongly associated with somatic than with cognitive
epressive symptoms (33). Taken together, these results
uggest that individual symptoms of depression may have
ifferential associations with several mechanisms, leading to
worse cardiac prognosis. Understanding the mechanisms
hat may lead to the worse cardiac prognosis observed in
epressed patients with CHD will be crucial for the design
f future trials (31). Future studies are therefore needed to
valuate the mechanisms that may be involved in the
eleterious effects of sleeping difficulties, fatigue, appetite
roblems, and psychomotor changes on CV prognosis.
The strengths of this study include the cohort size, the
rospective ascertainment of CV morbidity and mortality
ith a large number of events, and the detailed baseline
ssessment that allowed adjustment for important con-
ounding variables.
tudy limitations. First, this study included only outpa-
ients with stable CHD, so we cannot comment on the
ifferential effects of depressive symptoms in healthy people
r in patients after acute coronary syndromes.
Second, the participants in this study were mainly older
en. Therefore, the results may not be generalizable to
omen or to other patient populations. However, we
djusted for age and sex and found no indication for any
nteraction with age or sex.
Third, although depressive symptoms are independently
ssociated with poor CV prognosis in patients with CHD,
e cannot completely rule out the possibility that this
ssociation is confounded by worse underlying CV disease
37) or other comorbidities (38).
Finally, although the HRs and p values suggest that
omatic symptoms were more strongly associated with
epression than cognitive symptoms, the CIs surrounding
hese estimates had substantial overlap, so further research is
ecessary before any definitive conclusions can be drawn.
onclusions
e found that somatic symptoms of depression were respon-
ible for the increased risk for CV events in patients with stable
HD. Hopefully, this finding will lead to the development of
n
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esults of this study indicate the need for future research
irected at the identification of the underlying pathophysio-
ogical processes by which somatic depressive symptoms con-
ribute to prognosis in patients with CHD and to the testing of
nterventions to alleviate the associated risk.
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